Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5413945 | 1.00 | GLA (0.51) | GLACYP3A4CYP2C19GAAALDH1A1 | |
| SCHEMBL8276017 | 0.84 | MMP1 (0.40) | GLAALDH1A1TSHRHTTSMN1; SMN2 | |
| SCHEMBL12721762 | 0.80 | CA2 (0.36) | HPGD | |
| SCHEMBL16964806 | 0.77 | KDM4E (0.46) | CYP3A4CYP2C19GAAALDH1A1TSHR | |
| SCHEMBL3056303 | 0.77 | KDM4E (0.46) | CYP3A4CYP2C19GAAALDH1A1TSHR | |
| SCHEMBL8483745 | 0.77 | CYP3A4 (0.50) | CYP3A4CYP2C19GAAALDH1A1TSHR | |
| SCHEMBL5479224 | 0.77 | CYP3A4 (0.50) | CYP3A4CYP2C19GAAALDH1A1TSHR | |
| SCHEMBL12196226 | 0.77 | CYP3A4 (0.50) | CYP3A4CYP2C19GAAALDH1A1TSHR | |
| SCHEMBL12022410 | 0.74 | PKM (0.58) | GLAALDH1A1HTTSMN1; SMN2PKM | |
| SCHEMBL8488986 | 0.74 | CYP3A4 (0.47) | CYP3A4CYP2C19GAAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20060089357-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | US | disclosed |
| US-7030116-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1515726-A1 | MORPHOLINE AND TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2004002491-A1 | MORPHOLINE AND TETRAHYDROPYRAN DRIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACUETICALS INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | GLA 92/4885CYP3A4 1919/4885CYP2C19 1680/4885 |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | GLA 95/4885CYP3A4 1988/4885CYP2C19 1827/4885 |
| US-20060089357-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | GLA 92/4885CYP3A4 1919/4885CYP2C19 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.